A phase I trial (NCT00351949) tested this drug as monotherapy in 21 metastatic RCC showing both sustained CD8+ T cell activation and an increase in the percentage of long-lived effector-memory CD8+ T cell in all patients at doses above 6 mg; seven of eight evaluable patients dosed at 6 mg experienced stable disease at 3 months compared with only three of 11 in the lower dose group (p = 0.015) [53]. Here, CD8A is linked to renal cell carcinoma.